A revolutionary anti-cancer drug that has been approved by the Australian Therapeutic Goods Administration will give hope to Tasmanian patients. The drug will be marketed as Venclexta and has been approved for Australian patients with relapsed or refractory CLL with no other treatment options available, or with a mutation that makes the disease resistant to the usual treatment options.